Collegium Pharmaceutical, Inc. COLL Segment — Income Tax Expense (Benefit)

Similar metrics at other companies

ELFReportable Segment — Income Tax Expense (Benefit)

$14.49M+60.6%

SNDAReportable Segment — Income Tax Expense (Benefit)

$208K+177%

GCMGReportable Segment — Income Tax Expense (Benefit)

$3.14M-12.7%

BKSYReportable Segment — Income Tax Expense (Benefit)

$0+100%

DBRGReporting Segment — Income Tax Expense (Benefit)

-$8K-103%

ZVRAReportable Segment — Income Tax Expense (Benefit)

-$6.91M-485%

Questions, answered.

What is Collegium Pharmaceutical, Inc.'s segment — income tax expense (benefit)?

Collegium Pharmaceutical, Inc. (COLL) reported segment — income tax expense (benefit) of $4.24M in Q1 2026.

How has Collegium Pharmaceutical, Inc.'s segment — income tax expense (benefit) changed year-over-year?

Collegium Pharmaceutical, Inc.'s segment — income tax expense (benefit) increased by 502.0% year-over-year, from $705K to $4.24M.

What is the long-term trend for Collegium Pharmaceutical, Inc.'s segment — income tax expense (benefit)?

Over 3 years (2022 to 2025), Collegium Pharmaceutical, Inc.'s segment — income tax expense (benefit) has grown at a 97.8% compound annual growth rate (CAGR), from -$3.85M to $29.75M.

What does segment — income tax expense (benefit) mean?

This metric captures the total provision for income taxes or the benefit recognized by the business segment during the reporting period. It reflects the tax impact of the segment's operational profitability and applicable jurisdictional tax rates. Investors use this to assess the effective tax burden on the segment's pre-tax earnings.